Osmotica to Present at Barclays Global Healthcare Conference 2021
March 03, 2021 17:00 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
Osmotica to Present at 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021 16:30 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
February 01, 2021 16:30 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ap9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i)AMENDMENT The Form 8.1(a) dealings disclosure announcement made on January 27, 2020...
DIRECTOR DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
January 27, 2021 17:05 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- fAp9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL ...
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
January 27, 2021 17:05 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ap9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL ...
Rule 2.10 Announcement
January 27, 2021 17:00 ET
|
Osmotica Holdings US LLC
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH...
Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets
December 29, 2020 17:15 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has...
Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas
December 02, 2020 07:01 ET
|
Osmotica Holdings US LLC
Adamas to acquire global rights to OSMOLEX ER® for $7.5 million Company to focus on maximizing commercial opportunity for Upneeq™ BRIDGEWATER, N.J., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica...
RVL Pharmaceuticals, Inc. Strengthens Leadership Team as Commercial Launch of Upneeq® Expands
November 18, 2020 08:15 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), announced the addition of Dr. Raymond...
Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual London Healthcare Conference
November 12, 2020 16:30 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...